Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 15/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HK1 | P19367 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403432 | 0.82 | XDH (1.00) | XDH | |
| SCHEMBL2881243 | 0.78 | XDH (1.00) | XDH | |
| SCHEMBL1399849 | 0.77 | ALDH1A1 (0.56) | XDHALDH1A1MAPTHPGDHK1 | |
| SCHEMBL5392045 | 0.74 | GSK3B (0.72) | XDHALDH1A1HPGDRAB9A | |
| SCHEMBL4136769 | 0.74 | BACE1 (0.72) | XDHHPGD | |
| SCHEMBL3328576 | 0.74 | PTGES (0.47) | — | |
| SCHEMBL5381098 | 0.73 | XDH (0.72) | XDH | |
| SCHEMBL4142364 | 0.73 | XDH (0.61) | XDH | |
| SCHEMBL4149108 | 0.73 | XDH (0.77) | XDH | |
| SCHEMBL4150133 | 0.72 | BACE1 (0.57) | XDHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| CN-101084198-A | Substituted amino-pyrimidones and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-101084199-A | Substituted amino-compounds and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | XDH 951/4885ALDH1A1 2591/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.